Synthesis and evaluation of radiolabeled porphyrin derivatives for cancer diagnoses and their nonradioactive counterparts for photodynamic therapy

  • RSC Med Chem. 2022 Sep 22;13(12):1565-1574. doi: 10.1039/d2md00234e.
Nur Izni Ramzi  1 ,  Kenji Mishiro  2 ,  Masayuki Munekane  1 ,  Takeshi Fuchigami  1 ,  Xiaojun Hu  3 ,  Renata Jastrząb  4 ,  Yoji Kitamura  5 ,  Seigo Kinuya  6 ,  Kazuma Ogawa  1  2
Affiliations
  • 1. Graduate School of Pharmaceutical Sciences, Kanazawa University Kakuma-machi Kanazawa Ishikawa 920-1192 Japan [email protected].
  • 2. Institute for Frontier Science Initiative, Kanazawa University Kakuma-machi Kanazawa Ishikawa 920-1192 Japan.
  • 3. Center for Molecular Recognition and Biosensing, School of Life Sciences, Shanghai University Shanghai 200444 China.
  • 4. Faculty of Chemistry, Adam Mickiewicz University of Poznan Uniwersytetu Poznanskiego 8 Poznan 61-614 Poland.
  • 5. Research Center for Experimental Modeling of Human Disease, Kanazawa University Takara-machi 13-1 Kanazawa Ishikawa 920-8640 Japan.
  • 6. Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa University Takara-machi 13-1 Kanazawa Ishikawa 920-8641 Japan.
PMID: 36561065 DOI: 10.1039/d2md00234e
Abstract

Radioiodinated porphyrin derivatives and the corresponding nonradioactive iodine introduced compounds, [125I]I-TPPOH ([125I]3), [125I]I-l-tyrosine-TPP ([125I]9), I-TPPOH (3), and I-l-tyrosine-TPP (9) were designed, synthesized, and evaluated by in vitro and in vivo experiments. In cytotoxicity assays, 3 and 9 exhibited significant cytotoxicity under light conditions but did not show significant cytotoxicity without light irradiation. Biodistribution experiments with [125I]3 and [125I]9 showed similar distribution patterns with high retention in tumors. In photodynamic therapeutic (PDT) experiments, 3 and 9 at a dose of 13.6 μmol kg-1 weight with 50 W single light irradiation onto the tumor area significantly inhibited tumor growth. These results indicate that the iodinated porphyrin derivatives [123/natI]3 and [123/natI]9 are promising Cancer theranostic agents.